The price of LFCR is predicted to go up -38.72%, based on the high correlation periods with ASYS. The similarity of these two price pattern on the periods is 91.57%.
LFCR
ASYS
Down: -38.72%Similarity: 91.57%
LFCR Revenue Forecast
LFCR EPS Forecast
LFCR FAQs
What is bull’s view on LFCR?
Lifecore Biomedical (LFCR) stock is currently trading at $5.93, down 2.62% from its last close. Despite better-than-expected Q2 FY2025 results, including an 8% revenue increase to $32.6M and new strategic projects, the company faces challenges such as rising expenses and a net loss of $6.6M. Analysts are divided, with a "Hold" rating at $6 and a "Strong Buy" target of $10, reflecting mixed sentiment on its growth potential and financial health.
What is bear's view on LFCR?
LFCR stock currently trades at $7.01, reflecting a 5.3% gain after better-than-expected Q2 results. However, the company faces challenges, including a net loss of $6.6 million and rising administrative expenses, which could limit near-term upside. Analysts are divided, with a Hold rating at $6 (-21.26% downside) and a Strong Buy at $10 (+36.8% upside), suggesting mixed sentiment.
What is LFCR revenue forecast for next quarter?
The market consensus for LFCR's revenue in the upcoming quarter is projected to be approximately $37.537M USD.
What is LFCR eps forecast for next quarter?
The market consensus for LFCR's eps in the upcoming quarter is projected to be approximately $0.04 USD.
Craig-Hallum analyst Matthew Hewitt raised the firm's price target on Lifecore to $10 from $8 and keeps a Buy rating on the shares. Lifecore's investor day was successful, with management showcasing the company's 5-head filler capabilities and the strong demand for its business, the analyst tells investors in a research note.